When multiple myeloma relapses

RESPOND with a treatment studied in 860 patients with relapsed multiple myeloma*

KRdKd

ASPIRE: a pivotal phase 3 study1

Adapted from Stewart et al.1


Survival rates have improved for multiple myeloma patients but relapse is still an issue, so there remains a need for new treatment approaches.1

Kyprolis® has been studied in combination with standard of care regimens to determine how it improves key efficacy endpoints.

Design:
The ASPIRE study was a randomised, open-label, multicentre, phase 3 study.1

Aim:
To evaluate the safety and efficacy of Kyprolis® with lenalidomide and weekly dexamethasone vs lenalidomide and weekly dexamethasone alone in patients with relapsed multiple myeloma. 1

Population:
792 patients with relapsed multiple myeloma who had received 1–3 previous therapeutic regimens.1

Primary endpoint:
Progression-free survival.1

Secondary endpoints:
Included overall survival, the rate of overall response (partial response or better), duration of response, health-related quality of life, and safety.1

See the detailed treatment regimens in the ASPIRE study See the efficacy results from the ASPIRE study

*396 patients received KRd in the pivotal phase 3 ASPIRE study1 and 464 patients received Kd in the head-to-head phase 3 ENDEAVOR study2

Please read the SmPC for full comprehensive safety information

References

  1. Stewart AK et al. N Engl J Med 2015;372:142–152.
  2. Dimopoulos MA et al. Lancet Oncol 2016;17:27–38.

Terms of Use

The information contained in this site is for European healthcare professionals only.

Kyprolis